Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making

拉马纳亚克先生在生物制药公司开发和交易方面拥有超过15年的经验

Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas

在多个治疗领域的成功临床合作、并购、许可资产和战略融资举措方面有着良好的业绩记录

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ('CureVac'), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ('mRNA'), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024..

德国TÜBINGEN和波士顿，MA/ACCESSWIRE/2024年4月24日/CureVac N.V.（纳斯达克：CVAC）（“CureVac”），一家开发基于信使核糖核酸（“mRNA”）的新型转化药物的全球生物制药公司，今天宣布Thaminda Ramanayake已被任命为首席商务官，自2024年6月1日起生效。。

'Thaminda's extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across multiple therapeutic areas,' said Dr. Alexander Zehnder, Chief Executive Officer of CureVac.

CureVac首席执行官亚历山大·森德（AlexanderZehnder）博士说：“Thaminda在推进公司战略、业务发展和加强特定领域的战略合作伙伴关系方面的丰富经验，将成为CureVac的巨大资产，因为我们致力于在多个治疗领域开发一流的mRNA疫苗和药物。”。

'Mr. Ramanayake is an accomplished strategist whose distinctive leadership and advisory expertise will make him an essential thought partner in accelerating the development of impactful infectious disease, oncology and molecular therapies.'.

'先生。拉马纳亚克是一位多才多艺的战略家，其独特的领导力和咨询专业知识将使他成为加速发展有影响力的传染病，肿瘤学和分子疗法的重要思想合作伙伴。”。

Mr. Ramanayake has built a strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives over more than 15 years of biopharma development and deal-making. He joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company's business development organization.

拉马纳亚克先生在超过15年的生物制药开发和交易过程中，在成功的临床合作、并购、许可资产和战略融资举措方面建立了良好的记录。他从Affini-T Therapeutics加入CureVac，担任首席商务官，负责创建公司的业务发展组织。

He previously served as Vice President and Global Head of Business Development in Oncology at Sanofi, where he established the Clinical Trial Supply Agreement Center of Excellence and negotiated collaborations valued in the hundreds of millions to billions of dollars. He also held positions at BioMarin Pharmaceuticals where he in-licensed numerous gene therapy and oligonucleotide-based assets in hearing loss, cardiology, neurology and other therapeutic areas, and at Amgen, where he negotiated a number of international commercialization agreements..

他曾担任赛诺菲副总裁兼肿瘤学业务发展全球负责人，在那里他建立了临床试验供应协议卓越中心，并谈判了价值数亿至数十亿美元的合作。他还曾在BioMarin Pharmaceuticals任职，在那里他获得了听力损失，心脏病学，神经病学和其他治疗领域的众多基因治疗和基于寡核苷酸的资产的许可，并在安进（Amgen）谈判了多项国际商业化协议。。

With an educational background in both immunology and business, Mr. Ramanayake began his career as a scientist at Johnson & Johnson and later held a succession of Wall Street business development and consulting roles. He holds a master's degree in immunology from the University of Rochester Strong Medical Center and completed an MBA in Finance at the University of Rochester Simon School of Business.

拉马纳亚克先生拥有免疫学和商业方面的教育背景，他在强生公司（Johnson＆Johnson）开始了自己的科学家生涯，后来在华尔街担任了一系列商业发展和咨询角色。他拥有罗切斯特大学斯特朗医学中心免疫学硕士学位，并在罗切斯特大学西蒙商学院完成了金融MBA学位。

He holds a bachelor's degree in cellular, molecular and systems biology from Berea College..

他拥有伯里亚学院细胞、分子和系统生物学学士学位。。

'With promising data accumulating in CureVac's vaccine programs and the first clinical results in oncology anticipated later this year, it is an exciting time to join this pioneering team,' said Mr. Ramanayake. 'My career has centered on immunology and oncology, so I have an immense appreciation for the decades of research CureVac has contributed to the mRNA field.

拉马纳亚克说：“随着CureVac疫苗项目积累的有希望的数据以及预计今年晚些时候在肿瘤学方面取得的第一个临床结果，加入这个开创性团队是一个令人兴奋的时刻。”我的职业生涯集中在免疫学和肿瘤学上，因此我非常感谢CureVac几十年来对mRNA领域的研究。

One of the benefits of mRNA is its potential to deliver transformative medicines widely and equitably, offering greater access compared to other modalities. CureVac combines industry-shaping technology and outstanding talent, and I look forward to contributing to the company's mission to use therapeutic mRNA to transform people and patients' lives.'.

mRNA的好处之一是它有可能广泛而公平地提供转化药物，与其他方式相比，它提供了更多的途径。CureVac结合了行业塑造技术和杰出人才，我期待着为公司的使命做出贡献，即使用治疗性mRNA来改变人们和患者的生活。”。

About CureVac

关于CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.

CureVac（纳斯达克股票代码：CVAC）是信使RNA（mRNA）技术领域的全球生物制药公司，在开发，优化和制造这种用于医疗目的的多功能生物分子方面拥有20多年的专业知识。CureVac专有技术的原理是使用优化的mRNA作为数据载体，指导人体产生能够抵抗多种疾病的自身蛋白质。

In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies.

2020年7月，CureVac与GSK合作，共同开发基于CureVac第二代mRNA技术的传染病预防性疫苗新产品。这种合作后来扩展到开发第二代COVID-19候选疫苗和改进的mRNA疫苗技术。

Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S.

基于其专有技术，CureVac在预防性疫苗、癌症治疗、抗体治疗和罕见疾病治疗领域建立了一条深入的临床管道。CureVac N.V.的总部位于德国蒂宾根，在德国、荷兰、比利时、瑞士和美国的工厂拥有1100多名员工。

Further information can be found at www.curevac.com..

更多信息请访问www.curevac.com。。

CureVac Media Contact

CureVac媒体联系人

Patrick Perez, Junior Manager Public Relations

Patrick Perez，公共关系初级经理

CureVac, Tübingen, Germany

CureVac，德国蒂宾根

T: +49 7071 9883-1831

T： +49 7071 9883-1831

M: +49 151 14 115247

M： +49 151 14 115247

patrick.perez@curevac.com

patrick.perez@curevac.com

CureVac Media and Investor Relations Contact

CureVac Media和投资者关系联系人

Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations

Sarah Fakih博士，企业传播和投资者关系副总裁

CureVac, Tübingen, Germany

CureVac，德国蒂宾根

T: +49 7071 9883-1298

T： +49 7071 9883-1298

M: +49 160 90 496949

M： +49 160 90 496949

sarah.fakih@curevac.com

sarah.fakih@curevac.com

Forward-Looking Statements CureVac

前瞻性声明CureVac

This press release contains statements that constitute 'forward looking statements' as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.

本新闻稿包含构成1995年《美国私人证券诉讼改革法案》中定义的“前瞻性声明”的声明，包括表达CureVac N.V.的意见、期望、信念、计划、目标、假设或预测的声明。

and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the 'company') regarding future events or future results, in contrast with statements that reflect historical facts.

和/或其全资子公司CureVac SE、CureVac Manufacturing GmbH、CureVac Inc.、CureVac Swiss AG、CureVac Corporate Services GmbH、CureVac RNA Printer GmbH、CureVac Belgium SA和CureVac Netherlands B.V.（以下简称“公司”）关于未来事件或未来结果的陈述，与反映历史事实的陈述形成对比。

Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as 'anticipate,' 'intend,' 'believe,' 'estimate,' 'plan,' 'seek,' 'project,' or 'expect,' 'may,' 'will,' 'would,' 'could,' 'potential,' 'intend,' or 'should,' the negative of these terms or similar expressions.

例子包括讨论公司疫苗和候选治疗药物的潜在功效以及公司的战略、融资计划、现金跑道、增长机会和市场增长。在某些情况下，您可以通过诸如“预期”、“打算”、“相信”、“估计”、“计划”、“寻求”、“项目”或“预期”、“可能”、“将会”、“可能”、“潜在”、“打算”或“应该”等术语来识别此类前瞻性陈述，这些术语或类似表达的负面影响。

Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncerta.

前瞻性陈述基于管理层当前的信念和假设以及公司目前可用的信息。然而，这些前瞻性声明并不能保证公司的业绩，您不应过度依赖这些声明。前瞻性陈述受到许多风险、不确定性和其他可变情况的影响，包括全球经济状况不佳、全球金融市场持续不稳定和波动、获得资金的能力、进行当前和未来临床前研究和临床试验的能力、时间、费用和不确定性。

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov .

有关更多信息，请参考公司向美国证券交易委员会（SEC）提交的报告和文件。您可以访问SEC网站www.SEC.gov上的EDGAR获得这些文件。

SOURCE: CureVac

来源：CureVac

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿